Epigenetic targets in B- and T-cell lymphomas : latest developments
Ribeiro, Marcelo L. ![ORCID Identifier](/img/uab/orcid.ico)
(Sao Francisco University Medical School)
Sánchez Vinces, Salvador ![ORCID Identifier](/img/uab/orcid.ico)
(Sao Francisco University Medical School)
Mondragón, Laura ![ORCID Identifier](/img/uab/orcid.ico)
(Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Roué, Gaël ![ORCID Identifier](/img/uab/orcid.ico)
(Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Date: |
2023 |
Abstract: |
Non-Hodgkin's lymphomas (NHLs) comprise a diverse group of diseases, either of mature B-cell or of T-cell derivation, characterized by heterogeneous molecular features and clinical manifestations. While most of the patients are responsive to standard chemotherapy, immunotherapy, radiation and/or stem cell transplantation, relapsed and/or refractory cases still have a dismal outcome. Deep sequencing analysis have pointed out that epigenetic dysregulations, including mutations in epigenetic enzymes, such as chromatin modifiers and DNA methyltransferases (DNMTs), are prevalent in both B- cell and T-cell lymphomas. Accordingly, over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of these entities, and a few specific inhibitors have already been approved for clinical use. Here we summarize the main epigenetic alterations described in B- and T-NHL, that further supported the clinical development of a selected set of epidrugs in determined diseases, including inhibitors of DNMTs, histone deacetylases (HDACs), and extra-terminal domain proteins (bromodomain and extra-terminal motif; BETs). Finally, we highlight the most promising future directions of research in this area, explaining how bioinformatics approaches can help to identify new epigenetic targets in B- and T-cell lymphoid neoplasms. |
Grants: |
Ministerio de Economía y Competitividad PID2021-391230OB-C21
|
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by-nc.ico) |
Language: |
Anglès |
Document: |
Ressenya ; recerca ; Versió publicada |
Subject: |
BET inhibitors ;
Bioinformatics ;
Clinical testing ;
DNMT ;
Drug combination ;
Epigenetics ;
EZH2 ;
HAT ;
HDAC ;
Non-hodgkin's lymphoma |
Published in: |
Therapeutic Advances in Hematology, Vol. 14 (1-12 2023) , ISSN 2040-6215 |
DOI: 10.1177/20406207231173485
PMID: 37273421
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) >
Josep Carreras Leukaemia Research Institute Articles >
Research articlesArticles >
Published articlesArticles >
Reviews
Record created 2024-03-07, last modified 2024-05-04